Related Experiment Video

Updated: Aug 21, 2026

Modeling Chemotherapy Resistant Leukemia In Vitro
08:41

Modeling Chemotherapy Resistant Leukemia In Vitro

Published on: February 9, 2016

[Study on effect of berbamine on multidrug resistance leukemia K562/Adr cells]

Qing-hua Dong1, Shu Zheng, Rong-zhen Xu

  • 1Cancer Institute, The Second Affiliated Hospital of Zhejiang University, Hangzhou (310009).

Zhongguo Zhong Xi Yi Jie He Za Zhi Zhongguo Zhongxiyi Jiehe Zazhi = Chinese Journal of Integrated Traditional and Western Medicine
|October 22, 2004
PubMed
Abstract

Insights

Berbamine induces apoptosis in multidrug-resistant leukemia K562/Adr cells by activating Caspase-3. This compound also reverses drug resistance by reducing mdr-1 gene expression, offering a potential therapeutic strategy.

Area of Science:

  • Pharmacology
  • Molecular Biology
  • Cancer Research

Background:

  • Multidrug resistance (MDR) in leukemia poses a significant challenge to effective treatment.
  • Leukemia K562/Adr cells exhibit resistance to conventional chemotherapy.
  • Understanding the mechanisms of MDR is crucial for developing novel therapeutic interventions.

Purpose of the Study:

  • To investigate the effects of berbamine on apoptosis in multidrug-resistant leukemia K562/Adr cells.
  • To elucidate the mechanism by which berbamine induces apoptosis and reverses drug resistance.

Main Methods:

  • MTT assay to determine IC50 values.
  • Flow cytometry for apoptosis analysis (Annexin V FITC-PI), cell cycle, and protein expression (Caspase-3, P-GP).
  • RT-PCR to analyze mdr-1 gene expression.

Main Results:

  • Berbamine inhibited K562/Adr cell growth in a dose-dependent manner.
  • Berbamine induced apoptosis and increased Caspase-3 protein expression.
  • Berbamine reduced mdr-1 mRNA and protein expression, enhancing drug accumulation.

Conclusions:

  • Berbamine activates Caspase-3, leading to apoptosis in K562/Adr cells.
  • Berbamine effectively reverses multidrug resistance by downregulating mdr-1 gene expression.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...